Another TKI under clinical evaluation.
Flumatinib — a derivative of imatinib — may have superior efficacy compared with imatinib as frontline treatment in patients with 26chronic myeloid leukemia in chronic phase, according to the results of an open-label, randomized phase 3 study presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Both therapies had comparable safety profiles, the researchers found.
https://www.hematologyadvisor.com/home/conference-coverage/asco-2019/chr...